Welcome to our dedicated page for VVY news (Ticker: VVY), a resource for investors and traders seeking the latest updates and insights on VVY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VVY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VVY's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Vivoryon Therapeutics N.V. announces participation in two key investor conferences:
- Van Lanschot Kempen Life Sciences Conference on April 25-26, 2023, featuring one-on-one meetings in Amsterdam.
- Bio€quity Europe on May 14-16, 2023, with a presentation scheduled for May 16, 2023, at 10:44 am IST in Dublin.
As a clinical-stage biotechnology company, Vivoryon focuses on developing small molecule medicines aimed at modulating pathologically altered proteins, including its lead program, varoglutamstat, which targets Alzheimer’s disease in Phase 2 clinical development. The company is committed to advancing treatments for severe diseases, utilizing extensive expertise in protein modifications.